Mustang Bio, Inc. carries no debt; cash flow comfortably covers obligations.

Mustang Bio, Inc.'s free cash flow has increased -53.87% from $-11.41M last year to $-5.26M, signaling increasing performance

Mustang Bio, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Mustang Bio, Inc.'s debt has increased relative to shareholder equity from -0.23 last year to 0.00 today, signaling weakened financials

Mustang Bio, Inc. has a net cash position, so leverage is healthy.

Mustang Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Mustang Bio, Inc. has insufficient data to evaluate this check.

Mustang Bio, Inc.'s short-term assets of $17.59M exceed its short-term liabilities of $7.91M

Mustang Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mustang Bio, Inc.'s return on equity of -34.23%, is lower than 15.00%, indicating bad performance

Mustang Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Mustang Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Mustang Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Mustang Bio, Inc. has negative free cash flow, indicating cash burn

Mustang Bio, Inc.'s yearly earnings has increased -87.80% since last year from $-15.75M to $-1.92M, signaling increasing performance

Mustang Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -45.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mustang Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Mustang Bio, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Mustang Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Mustang Bio, Inc. has insufficient data to evaluate this check.

Mustang Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mustang Bio, Inc. is overvalued relative to its fair value price of 0.07 based on EBITDA multiple model

Mustang Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Mustang Bio, Inc. has insufficient data to evaluate this check.

Mustang Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mustang Bio, Inc. has a price-to-book ratio of 0.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Mustang Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue